Vriligy Tablet is a pharmacological intervention prescribed for the treatment of PE (premature ejaculation) in adult men. The active pharmaceutical ingredient in Vriligy is Dapoxetine, a SSRI (selective serotonin reuptake inhibitor) that has been specially tailored for the on-demand treatment of PE. Unlike other SSRIs designed for the treatment of depression and various psychological disorders, Dapoxetine’s unique pharmacokinetic profile with a rapid onset of action and a short half-life makes it suitable for the treatment of PE, where it is required to be used only when needed. The typical presentation of Vriligy Tablets is in dosages ranging from 30mg to 60mg.

The Dejac T Tablet is a medicinal product extensively utilized in the management of premature ejaculation in adult men. This pharmaceutical concoction harmonizes two pivotal active ingredients, namely Dapoxetine, a mechanism-driven selective serotonin reuptake inhibitor (SSRI) heralded for its prominence in extending the latency time before ejaculation, and Tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor that bolsters erectile function by enhancing blood flow to the penis. Addressing both erectile dysfunction (ED) and premature ejaculation, Dejac T Tablet appears as a commendable solution, harboring the capacity to significantly improve sexual performance and satisfaction. It operates by a sophisticated action mechanism that not only facilitates the achievement and maintenance of an erection but also delays the ejaculatory reflex, cultivating a dual therapeutic front in sexual health.